With a median follow-up of 9 years, discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic phase chronic myeloid leukaemia (CML) was reported in 43% of 548 evaluable CML patients, in a population-based setting. Patients interrupting TKI therapy outside a clinical trial setting had good outcomes.
Dr Hjalmar Flygt (Uppsala University Hospital, Sweden) presented data extracted from the Swedish CML registry about patients stopping TKI therapy outside of clinical trials in chronic phase CML [1]. Studies have shown that 40-50% of patients with a deep molecular response (DMR, defined as MR4.0 or lower) successfully remained TKI treatment-free. In the current Swedish Guidelines for CML, stopping TKI therapy can be considered in patients treated with a TKI ≥5 years and an MR4.0 or lower for at least 2 years.
CML patients diagnosed between 2007-2012 (n=584) were analysed, of whom 234 of the 548 evaluable patients (43%) had stopped treatment with TKI ≥1 month. Most interrupted TKI therapy because they had achieved durable MR (56%); other reasons included adverse events (18%), or stem cell transplantation (13%).
In an analysis aimed at determining outcomes of patients treated outside of a clinical trial setting, Dr Flygt pointed out that 29% stopped while enrolled in a clinical trial, whereas 70% stopped their TKI therapy outside a study setting. Median time from diagnosis to TKI stop while in a study was 4.2 years (IQR: 3.6-5.2), and 6.0 years (IQR: 4.0-7.5) for those not enrolled in a study. In total, 48.9% patients had re-initiated TKI treatment at a median of 0.4 years (IQR 0.3-0.6) after stopping TKI. Of those stopping TKI outside a study setting, the probability of remaining TKI treatment-free at 22 months was 61%.
-
- Flygt H, et al. High level of successful TKI discontinuation outside clinical trials – a population-based study from the Swedish CML registry. EHA25 Virtual, 11-21 June 2020, Abstract S174.
Posted on
« Patients with lower-risk MDS benefit from imetelstat Next Article
Asciminib monotherapy in Ph+ CML: major molecular responses »
Table of Contents: EHA 2020
Featured articles
Myeloid
VIALE-A: newly diagnosed chemo-ineligible AML
DEC10-VEN superior to intensive chemotherapy in high-risk AML
Magrolimab plus azacitidine: good ORR in MDS/AML
Asciminib monotherapy in Ph+ CML: major molecular responses
CML TKI interruption: Swedish registry results
Patients with lower-risk MDS benefit from imetelstat
Better outcomes adding enasidenib to azacitidine in mIDH2-AML
Lymphoid
PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
Promising first-in-human trial of epcoritamab in B-NHL
Two trials: acalabrutinib in CLL
Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia
Deep responses in R/R CLL with venetoclax monotherapy
MRD assessment post-CAR-T predicts ALL allo-HSCT bridging
Plasma Cell Dyscrasias
Daratumumab for light-chain amyloidosis
Isatuximab triplet improves PFS in R/R MM
Initial results from CAR-T cell therapy in MM: KarMMa
Graft-Versus-Host Disease
GRAVITAS-301: improved complete aGVDH response
Ruxolitinib improves steroid-refractory aGVHD across subtypes
Benign Haematology
Paroxysmal nocturnal haemoglobinuria treatment with pegcetacoplan
Mitapivat, a pyruvate kinase-R activator, in SCD is safe with early efficacy results
SCD LentiGlobin gene therapy: new data on VOC and ACS
Paediatric Haematology
Venetoclax + navitoclax promising for R/R ALL or LL
Nivolumab/brentuximab vedotin in R/R HL: good CMR rates
Bench-to-Bedside Science from the Presidential Symposium
Microbiome predicts B-ALL predisposition
Netrin-1 regulates haematopoietic stem cells
Unrecognised role of iron in neutrophil differentiation
Related Articles

DEC10-VEN superior to intensive chemotherapy in high-risk AML
Asciminib monotherapy in Ph+ CML: major molecular responses
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy